文献速递白血病

老年急性髓系白血病患者体能状态判定与治疗选择

Determination of fitness and therapeutic options in older patients with acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2021-01-12

该综述指出,尽管年龄、体能状态和合并症常用于判定老年AML患者是否适合强化治疗,但多项研究显示老年及传统上不适合的患者仍可从治疗中获益,提示其他疾病和患者因素具有预后价值。目前缺乏一致客观的体能评估,多参数老年评估工具更全面但受资源、标准化和预后共识限制。新出现的不同强度AML疗法使综合评估尤为重要,应个体化判定适合特定治疗并在临床试验中统一应用。

要点

  • 年龄、体能状态和合并症不足以单独判定老年AML患者的治疗适合性。
  • 多参数老年评估更全面,但受资源和标准化限制。
  • 应根据特定治疗综合评估体能,实现个体化治疗并统一用于临床试验。

核心结论

  • 老年AML患者治疗仍具挑战,需综合疾病和患者因素个体化判定体能以选择治疗。

研究设计与样本

  • 综述,探讨老年AML患者体能判定标准的演变及治疗选择。

主要发现

  • 多项研究显示老年及传统不适合患者接受治疗仍可改善结局,提示其他因素有预后价值。
  • 缺乏一致客观的体能评估,多参数老年评估受资源和标准化限制。

临床怎么用

  • 应综合评估患者是否适合特定治疗,实现个体化治疗。
  • 体能定义应统一应用于临床试验。

局限性

  • 多参数老年评估工具缺乏标准化和预后价值共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of older patients with AML remains challenging. Although age, performance status, and comorbidities are commonly employed to determine fitness for intensive treatment, several studies have demonstrated improved outcomes with treatment in older and classically unfit patients, highlighting the importance of other disease-related and patient-related factors that have prognostic value for treatment outcome in AML. However, consistent and objective assessments for fitness are lacking. Multi-parameter geriatric assessment tools offer more comprehensive evaluation, but are limited by the required resources and lack of standardization and consensus regarding prognostic value. These assessments are particularly important considering the emerging new AML therapies that represent a spectrum of intensities. Patients should therefore be evaluated holistically for fitness to receive a specific treatment, with the aim of providing individualized care, and such definitions of fitness should also consistently be applied to clinical trials. This review will examine evolving criteria for the determination of fitness among AML patients and discuss treatment options for older and/or unfit patients with AML.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Cortes JE, Mehta P. Determination of fitness and therapeutic options in older patients with acute myeloid leukemia. Am J Hematol. 2021. PMID: 33368536. doi:10.1002/ajh.26079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。